Offerings (SEC Form D)
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
Offerings at a glance — 2 offerings, 2 filings (one row per SEC file number)
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|
| 021-441822 | Apr 14, 2022 EDGAR ↗ | Apr 14, 2022 D EDGAR ↗ | 0 | $149,999,985 | $149,999,985 | Biotechnology |
| 021-375736 | Sep 17, 2020 EDGAR ↗ | Sep 17, 2020 D EDGAR ↗ | 0 | $250,000,000 | $250,000,000 | Biotechnology |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
Apr 14, 2022 D Biotechnology — $149,999,985 sold of $149,999,985 · 1 investors EDGAR ↗
| Filing | Form D filed Apr 14, 2022SEC file no. 021-441822 · accession 0001776985-22-000024 |
|---|
| Raise progress | $149,999,985 sold of $149,999,985 offered (100%) · $0 remaining · first sale Apr 11, 2022 |
|---|
| Filing timing | Date of first sale: Apr 11, 2022 · Form D filed: Apr 14, 2022 (3 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 1,657 days (4.5 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 1 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in GERMANY · formed more than five years before filing · revenue range: Over $100,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Sierk Poetting, Managing Director (Apr 14, 2022) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $149,999,985. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Sep 17, 2020 D Biotechnology — $250,000,000 sold of $250,000,000 · 2 investors EDGAR ↗
| Filing | Form D filed Sep 17, 2020SEC file no. 021-375736 · accession 0001209191-20-050787 |
|---|
| Raise progress | $250,000,000 sold of $250,000,000 offered (100%) · $0 remaining · first sale Sep 7, 2020 |
|---|
| Filing timing | Date of first sale: Sep 7, 2020 · Form D filed: Sep 17, 2020 (10 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,238 days (6.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 2 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Debt |
|---|
| Entity details | Organized in GERMANY · formed more than five years before filing · revenue range: Over $100,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Sierk Poetting, Managing Director (Sep 15, 2020)Signed by an authorized representative. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $250,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 2. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Apr 14, 2022. Industry as reported, by offering: All 2 offerings reported: Biotechnology (2020–2022).
Key people 10
Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|
| CH Christoph Huber | Director | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | — |
| HJ Helmut Jeggle | Director | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | 1 other issuer |
| JH Jens Holstein | Executive Officer | Germany (as filed: 2M) | Apr 14, 2022 on 1 of 2 filings listed on the latest filing | — |
| MM Michael Motschmann | Director | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | — |
| OT Ozlem Tureci | Executive Officer | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | — |
| RR Ryan Richardson | Executive Officer | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | — |
| SM Sean Marett | Executive Officer | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | 1 other issuer |
| SP Sierk Poetting | Executive Officer | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | — |
| US Ugur Sahin | Executive Officer | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | — |
| UW Ulrich Wandschneider | Director | Germany (as filed: 2M) | Sep 17, 2020 → Apr 14, 2022 on 2 of 2 filings listed on the latest filing | — |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Connections
Other issuers listing the same people:
Shared address: this business address appears on no other issuer's filings in our index. As of Oct 23, 2026, 5:45 PM ET.
Other offering types (Regulation A and Regulation Crowdfunding)
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Adviser registration (Form ADV)
Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Meta advertising
Meta advertising Meta Pixel and page links found on the sponsor's own site; ads from Meta's Ad Library where the API returns them
Not yet searched.
Sources to be searched: the sponsor's website (none on record yet; a sponsor's website is known only from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim or Form ADV Item 1.I of its matched adviser — we never look it up elsewhere) for Meta Pixel ids and Facebook / Instagram page links; Meta Ad Library API: not yet searched (API access pending). We never read facebook.com or instagram.com; readers get a link to Meta's public Ad Library instead.
Public profiles
Public profiles official links and public statements, each with its source and date
Not found in sources searched.
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website is known only from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim or Form ADV Item 1.I of its matched adviser — we never look it up elsewhere. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for issuers located outside the US (business address code as filed: 2M; jurisdiction of organization as filed: GERMANY) yet).
Export this report as PDF (all source links + data timestamp) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
Corrections log
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.
Email me the full report
The complete public-record profile for BioNTech SE, plus the weekly new-filings list.
What do you want to do?
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Request a correction
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsor response
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Claim this profile (sponsors)
Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.